ProQR Therapeutics Files 6-K for Q1 2025
Ticker: PRQR · Form: 6-K · Filed: May 8, 2025 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 6-K, foreign-private-issuer
Related Tickers: PRQR
TL;DR
ProQR Therapeutics (PRQR) filed its Q1 2025 6-K, updating financials as of March 31.
AI Summary
ProQR Therapeutics N.V. filed a Form 6-K on May 8, 2025, reporting its financial information as of March 31, 2025. The company, based in Leiden, The Netherlands, is a foreign private issuer and is subject to the 1934 Act. This filing serves as an update for the period ending March 31, 2025.
Why It Matters
This filing provides an update on ProQR Therapeutics' financial status and reporting for the first quarter of 2025, which is crucial for investors to assess the company's performance and financial health.
Risk Assessment
Risk Level: low — This is a routine financial reporting form (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Registrant
- 001-36622 (company) — Commission File Number
- 20250331 (date) — Conformed Period of Report
- 20250508 (date) — Filing Date
- Leiden, The Netherlands (location) — Principal Executive Offices
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to provide updated information to the SEC.
What is the reporting period for this filing?
The conformed period of report is March 31, 2025.
When was this Form 6-K filed?
This Form 6-K was filed on May 8, 2025.
Where are ProQR Therapeutics N.V.'s principal executive offices located?
ProQR Therapeutics N.V.'s principal executive offices are located at Zernikedreef 9, 2333 CK Leiden, The Netherlands.
Does ProQR Therapeutics N.V. file its annual reports under Form 20-F or 40-F?
ProQR Therapeutics N.V. files its annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 8, 2025 regarding ProQR Therapeutics N.V. (PRQR).